| The FinancialContent Network SocialPicks Community | MarketMinute Monitor | MarketMinute Market Updates | MarketMinute Stock News |
|
Tracked Blogger
|
Via BloggingStocks:
Filed under: Analyst reports, Pfizer (PFE), Market matters, Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Deere and Co (DE), Stocks to Buy, Potash Corp. of Saskatchewan (POT) TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all. Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (MRK) (Cramer's Take), Bristol-Myers (BMY) (Cramer's Take) and Lilly (LLY) (Cramer's Take). But there is one drug stock that is continually met with skepticism -- Sanofi Aventis (SNY) (Cramer's Take), the French vaccine and pharmaceutical maker run by Christian Viehbacher. The resistance is obvious, as his biggest two drugs are coming off patent very soon, and his hope is that by 2013 the company might again reach 2008 levels. Sounds like there's no reason to buy this one. Sounds like its 4% dividend isn't safe. Continue reading Cramer on BloggingStocks: Sanofi has lots of upside catalysts Cramer on BloggingStocks: Sanofi has lots of upside catalysts originally appeared on BloggingStocks on Mon, 23 Nov 2009 10:00:00 EST. Please see our terms for use of feeds. Permalink | Email this | Comments
Read the rest of original post »
|
|
|
IN THE PRESS |
|
|
|
|
|
|
| About | RSS | Feedback | Contact Us | Terms of Service | Privacy |
© 2009 FinancialContent Services, Inc. |
|
Data powered by FinancialContent. All Rights Reserved. Quotes delayed at least 20 minutes unless otherwise indicated. |
|
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. |